The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
The agreement could rise to $900 million if key commercial milestones are met
Health innovations are viewed more positively than food and agricultural technologies
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Subscribe To Our Newsletter & Stay Updated
